Catching cancer earlier

About STRIM

STRIM provides a cutting-edge training programme covering the scientific, technological, and socio-economic aspects of bioelectronic tool development for fast and precise cancer screening. By leveraging advanced molecular post-translational modifications (PTMs) of biofluid biomarkers, this programme will drive innovation in early multi-cancer detection.

Doctoral training in STRIM will encompass state-of-the art approaches for ultra-sensitive detection of PTM biomarkers as cancer screening tools by building on recent advances in electrochemiluminescence, aptamer and DNA microarrays and conducting polymer micro-structured electrodes. These techniques will reach new levels of specificity and overcome barriers to the realization of multiplexed diagnostics for enhanced cancer screening. All translational issues will be considered in harmonization with regulatory and health technology assessment and social acceptability will be screened in the population.

Through a multidisciplinary approach, STRIM will equip researchers with the expertise to develop, optimize, and translate next-generation screening technologies, ultimately improving early diagnosis and patient outcomes.

STRIMING
NEWS!

We are recruiting 13 PhD students for this challenging project!

Advancing Early Cancer Detection with Cutting-Edge Bioelectronic Tools

The STRIM Training Network is at the forefront of revolutionizing cancer screening. Our multidisciplinary consortium is developing fast, accurate, and highly sensitive bioelectronic tools that leverage advanced molecular receptors and nanobiotechnologies.

Our focus? Detecting aberrant post-translational modifications (PTMs)—crucial genomic and proteomic biomarkers that hold immense potential for early cancer detection. With growing evidence linking PTMs to various cancers, our approach is poised to transform screening efficiency and improve population health.

By integrating expertise across these domains, STRIM is shaping the future of next-generation cancer diagnostics. Stay tuned as we push the boundaries of precision medicine and early intervention.

#CancerResearch #Bioelectronics #EarlyDetection #Innovation #HealthTech

More information at :

STRIM KICK OFF MEETING

March, Copenhagen

HALL OF FAME

Download our leaflet

Download our poster

Download our pager

Transforming Cancer Detection for Better Outcomes

Cancer remains one of the biggest challenges for EU healthcare systems. Early detection is the key to successful treatment and improved survival rates. Through a high-impact scientific, social, and economic program, STRIM is developing cutting-edge screening technologies that have the potential to revolutionize cancer detection and significantly improve patient outcomes.

By advancing early screening methods, STRIM aims to enhance survival rates, reduce healthcare burdens, and drive innovation in cancer diagnostics.

Advancing Early Cancer Detection Through PTM Biomarkers

Emerging evidence highlights the critical role of post-translational modifications (PTMs) in DNA and protein biomarkers, demonstrating high specificity across multiple cancer types. To harness this potential, there is an urgent need for advanced biomaterials and sensor technologies capable of reliably linking genomic and proteomic PTMs to cancer status. These innovations must offer analytical precision and clinical reliability, paving the way for seamless translation into medical practice.

This transformative approach could revolutionize early cancer detection, enhancing population health while reducing the socio-economic burden of healthcare across Europe. Achieving this vision demands a multidisciplinary research and training ecosystem, equipping scientists with expertise across the entire innovation pipeline—from biomarker discovery and device fabrication to clinical integration and socio-economic evaluation

Empowering the Next Generation of Cancer Diagnostics Innovators

The STRIM programme trains and mentors 13 Doctoral Candidates (DCs), equipping them with cutting-edge expertise in bio(electro)chemical methods and technologies. These future pioneers develop robust, low-cost, portable, and user-friendly diagnostic devices capable of rapidly detecting PTM biomarkers of cancer with exceptional sensitivity and selectivity.

Beyond technical excellence, STRIM DCs gain a deep understanding of biomarker discovery, clinical validation, and the full innovation pipeline—from prototype development to mass manufacturing and real-world application in hospitals, clinics, and doctors’ offices.

The programme’s interdisciplinary and trans-sectoral network of leading researchers, industry experts, and clinicians will accelerate the translation of PTM detection technologies into clinical practice. The novel bio- and electrochemical devices developed by STRIM DCs will revolutionize cancer screening by identifying at-risk individuals earlier and enabling timely intervention.

WHO ARE WE?

THE STRIMERS

Backed by a powerhouse of 6 universities, 2 companies, 3 medical research centers, and 2 hospitals, STRIM unites world leaders in:

Bioinformatics & biomarker discovery
Bioreceptor selection & nanofabrication
Biosensor development & cancer research
Health technology assessment.

WHAT DO WE AIM?

STRIM major goal is to develop breakthrough approaches for cancer diagnosis, to translate the results into practical clinical tools enabling clinician’s evidence-based decision-making that actually changes clinical practice to improve patient outcomes.

HOW DO WE

Strim at a glance

The project ideology

We develop biomaterials targeting PTM cancer biomarkers for Multi-Cancer Early Detection using bioinformatic analysis of PTM biomarker panels and system biology-oriented approaches.

We develop high-performance bioelectronic and electrocatalytic assays for cancer screening by detecting glycosylation and methylation PTM biomarkers enabling early diagnosis of cancers and their types.

We develop new ultrasensitive electrochemiluminescence (ECL) detection devices and electrocatalytic electrode systems for multianalyte, multi-replicate, multi-sample analysis and multiplexed (up to 102 sites) ultrasensitive chronocoulometric and potentiometric DNA biosensor devices exploiting field effect transistors (FET) technology.

We investigate the ethical, participation, iatrogenic burden and regulatory aspects in an health technology assessment framework for cancer screening technologies.